Two Of The Cyclos Share At Least Three Ring Members (i.e., Bridged) (e.g., Morphinans, Etc.) Patents (Class 514/289)
-
Publication number: 20140194457Abstract: A compound of formula I is disclosed. Compounds of formula I are useful as analgesics, anti-inflammatory agents, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.Type: ApplicationFiled: March 12, 2014Publication date: July 10, 2014Applicant: Rensselaer Polytechnic InstituteInventor: Mark P. WENTLAND
-
Patent number: 8772310Abstract: The present invention provides a compound of formula I: wherein X?, R1, and R2 are as defined herein, and compositions thereof; useful as a peripheral mu opioid receptor antagonist.Type: GrantFiled: November 9, 2012Date of Patent: July 8, 2014Assignee: Wyeth LLCInventors: Charles K. Melucci, John Lokhnauth
-
Publication number: 20140187573Abstract: The application is directed to compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4a, and R4b are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.Type: ApplicationFiled: December 23, 2013Publication date: July 3, 2014Applicant: Purdue Pharma L.P.Inventors: Andrew KASSICK, Jeffrey LOCKMAN, Laykea TAFESSE
-
Publication number: 20140178473Abstract: There is provided a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form includes at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit including the same are also provided.Type: ApplicationFiled: October 11, 2013Publication date: June 26, 2014Applicant: IX BIOPHARMA PTE LTDInventors: Chin Beng Stephen LIM, Vivian Bruce SUNDERLAND, Yip Hang Eddy LEE
-
Publication number: 20140171436Abstract: The present invention is a method of treating antifolate neurotoxicity in a mammal suffering from or at risk of developing antifolate neurotoxicity, which comprises administering to the mammal a therapeutically effective amount of an NMDA antagonist, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 29, 2013Publication date: June 19, 2014Applicant: Syntrix Biosystems, Inc.Inventors: Barton Aron Kamen, John Anthony Zebala
-
Patent number: 8748450Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.Type: GrantFiled: July 24, 2013Date of Patent: June 10, 2014Assignee: Concert Pharmaceuticals, Inc.Inventor: Roger Tung
-
Publication number: 20140154180Abstract: This invention relates, e.g., to a method for designing or selecting on a computer a candidate small molecule amyloid binder or inhibitor, comprising: a) docking test compounds to the binding site or binding surface determined from the three-dimensional structure of a co-crystal of a protofilament of an amyloid protein bound to a small molecule which is known to bind to the amyloid protein, and (b) selecting test compounds which exhibit an energy below that of the small molecule used to form the co-crystal made in a), as candidate amyloid binders.Type: ApplicationFiled: July 16, 2012Publication date: June 5, 2014Applicant: The Regents of the University of CaliforniaInventors: David S. Eisenberg, Lin Jiang, Meytal Landau, Cong Liu
-
Publication number: 20140148475Abstract: 4-Hydroxybenzomorphans containing carboxamide or thiocarboxamide at the 3-position are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications. A compound of formula is disclosed, as are pharmaceutically acceptable acid addition salts, such as acetic, benzenesulfonic (besylate), benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid or p-toluenesulfonic acid salts. These compounds are useful for the treatment of pain.Type: ApplicationFiled: January 31, 2014Publication date: May 29, 2014Applicant: Rensselaer Polytechnic InstituteInventor: Mark P. WENTLAND
-
Patent number: 8716306Abstract: A compound of formula I is disclosed. Compounds of formula I are useful as analgesics, anti-inflammatory agents, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.Type: GrantFiled: April 5, 2013Date of Patent: May 6, 2014Assignee: Rensselaer Polytechnic InstituteInventor: Mark P. Wentland
-
Patent number: 8710072Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.Type: GrantFiled: September 18, 2009Date of Patent: April 29, 2014Assignee: Concert Pharmaceuticals, Inc.Inventors: Philip B. Graham, I. Robert Silverman
-
Publication number: 20140113925Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.Type: ApplicationFiled: December 27, 2013Publication date: April 24, 2014Applicant: Concert Pharmaceuticals, Inc.Inventor: Roger Tung
-
Patent number: 8703949Abstract: The present invention provides processes for the preparation of N-alkyl morphinans without the isolation of nor-morphinan intermediates. In particular, the invention provides tandem hydrolysis/alkylation reactions for the synthesis of N-alkyl morphinans.Type: GrantFiled: August 3, 2011Date of Patent: April 22, 2014Assignee: Mallinckrodt LLCInventors: Subo Liao, Peter X. Wang, David W. Berberich, Douglas C. Miller
-
Publication number: 20140107143Abstract: Compounds of formulas: are disclosed. The compounds are useful for ameliorating the side effects of therapeutic opiates.Type: ApplicationFiled: September 27, 2013Publication date: April 17, 2014Applicant: Rensselaer Polytechnic InstituteInventor: Mark P. WENTLAND
-
Publication number: 20140093577Abstract: The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles.Type: ApplicationFiled: October 3, 2013Publication date: April 3, 2014Applicant: NEOS THERAPEUTICS, LPInventors: Mark TENGLER, Paul Taskey, Daniel Lockhart, Russell McMahen
-
Publication number: 20140094482Abstract: A method of inhibiting hyperphosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system a FLNA-binding effective amount of a FLNA-binding benzazocine-ring compound or a pharmaceutically acceptable salt thereof such as a) an opioid receptor antagonist compound or b) a mixed opioid receptor agonist and antagonist (agonist/antagonist) compound, c) an opioid receptor agonist compound or d) an enantiomer of an opioid receptor interacting compound, that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1. The administered compound preferably contains at least four of the six pharmacophores of FIGS. 5-10.Type: ApplicationFiled: August 15, 2013Publication date: April 3, 2014Inventors: George B. Thornton, Hoau-Yan Wang, Lindsay Burns Barbier, Michael S. Zamloot
-
Patent number: 8680112Abstract: 4-Hydroxybenzomorphans containing carboxamide or thiocarboxamide at the 3-position are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.Type: GrantFiled: June 8, 2007Date of Patent: March 25, 2014Assignee: Rensselaer Polytechnic InstituteInventor: Mark P. Wentland
-
Publication number: 20140073562Abstract: A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.Type: ApplicationFiled: March 15, 2012Publication date: March 13, 2014Applicant: OPTINOSE ASInventor: Per Gisle Djupesland
-
Publication number: 20140050789Abstract: Provided are compositions comprising a benzodiazepine and a neurosteroid, containing one or both of the benzodiazepine and the neurosteroid in a subtherapeutic dose, and administration of such compositions for mitigation of an epileptic seizure. Further provided are compositions comprising a benzodiazepine, a neurosteroid, and an NMDA blocker, and administration of such compositions for mitigation of an epileptic seizure.Type: ApplicationFiled: August 12, 2013Publication date: February 20, 2014Applicant: The Regents of the University of CaliforniaInventors: Michael A. ROGAWSKI, Isaac N. PESSAH, Zhengyu CAO, Pamela J. LEIN
-
Publication number: 20140051718Abstract: Neurological disorders may be treated by administering a therapeutically effective amount of dextromethorphan and a therapeutically effective amount of a compound such as celecoxib that inhibits the metabolism of dextromethorphan, to a person in need thereof. The two compounds may be administered separately, or in a single dosage form or composition as described herein.Type: ApplicationFiled: July 16, 2013Publication date: February 20, 2014Applicant: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Publication number: 20140045880Abstract: Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.Type: ApplicationFiled: October 21, 2013Publication date: February 13, 2014Applicant: Avanir Pharmaceuticals, Inc.Inventors: Gerald Yakatan, James Berg, Laura E. Pope, Richard A. Smith
-
Publication number: 20140037727Abstract: A medicament tablet containing paracetamol (acetaminophen) as the (or an) active ingredient, and an encapsulated flavorant. The tablet may be swallowed in tablet form or may be dissolved or dispersed in water to form a palatable drink.Type: ApplicationFiled: October 8, 2013Publication date: February 6, 2014Applicant: Reckitt Benckiser Healthcare (UK) LimitedInventor: Paul Frederick Field
-
Patent number: 8637567Abstract: This invention provides compounds, compositions and methods for treating a cognitive disorder or memory disorder in animals that result from aging or other neurodegenerative condition. In particular, compounds of this invention can stimulate neural cell growth, increased amounts of cells containing a key enzyme needed for production of the cholinergic neurotransmitter, and can improve memory and cognitive function in animals who have experienced a loss of memory or cognitive function.Type: GrantFiled: October 13, 2010Date of Patent: January 28, 2014Assignee: Neuren Pharmaceuticals Ltd.Inventors: Peter David Gluckman, Jian Guan, Mary-Anne Woodnorth, Margaret Anne Brimble
-
Publication number: 20140023707Abstract: The present invention comprises a co-processed carbohydrate system, and formulations produced therefrom, which formulations are directly compressible into solid dosage forms, some of which rapidly and completely dissolve or disintegrate in the oral cavity within 60 seconds. The invention also comprises the solid dosage forms produced by directly compressing the co-processed carbohydrate system, some of which, when placed in the oral cavity, shall dissolve or disintegrate, preferably within about 60 seconds.Type: ApplicationFiled: September 27, 2013Publication date: January 23, 2014Applicant: SPI Pharma, Inc.Inventors: Gary T. Norman, Kalyan S. Nuguru, Arun F. Amin, Sarath Chandar
-
Publication number: 20140017346Abstract: Disclosed is a gelatin-free soft caramel including a soft caramel base mass that contains at least one polysaccharide hydrocolloid as texturing agent, a crystalline sweetener phase formed by isomaltulose, and a noncrystalline sweetener phase, wherein the caramel is gelatin-free. It can be made by providing a noncrystalline sweetener phase by dissolving at least one soluble sweetener in water, adding polysaccharide hydrocolloid, fat component, emulsifier and a part of the total amount of the isomaltulose to the noncrystalline sweetener phase, steam heating the mixture to a temperature of at least 100° C., adding the remaining isomaltulose to the heated mixture while stirring, incorporating air into the mixture and cooling.Type: ApplicationFiled: September 16, 2013Publication date: January 16, 2014Applicant: Sudzucker Aktiengesellschaft Mannheim/OchsenfurtInventors: Jorg Bernard, Kowalczyk Jorg
-
Publication number: 20140005215Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which relates to mophinan compounds useful as ?, ? and/or ? receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.Type: ApplicationFiled: December 4, 2012Publication date: January 2, 2014Applicant: Alkermes, Inc.Inventor: Alkermes, Inc.
-
Publication number: 20130345251Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.Type: ApplicationFiled: August 23, 2013Publication date: December 26, 2013Applicant: Rensselaer Polytechnic InstituteInventor: Mark P. WENTLAND
-
Publication number: 20130338182Abstract: Compounds of Formula (I) are disclosed. The variables R1-R11 are described herein. Certain compounds of Formula (I) are partial agonists of the mu, delta, and kappa opioid receptors, and are useful for treating pain and opioid addiction, with fewer side effects than conventional opioids. Methods for preparing the disclosed compounds, pharmaceutical compositions containing compounds of Formula (I), and methods of treating pain and opioid addiction in patients are also disclosed.Type: ApplicationFiled: December 23, 2011Publication date: December 19, 2013Applicant: PHEONIX PHARMALABS, INC.Inventor: John Lawson
-
Publication number: 20130337148Abstract: The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to temperatures above that at which the active components typically degrade without concern for loss of the desired activity.Type: ApplicationFiled: March 29, 2013Publication date: December 19, 2013Applicant: MONOSOL RX, LLCInventors: Robert K. Yang, Richard C. Fuisz, Garry L. Myers, Joseph M. Fuisz
-
Patent number: 8609684Abstract: A composition for increasing the bioavailability of Acetaminophen in humans and animals, comprising Acetaminophen, a first water soluble surfactant having a cloud point greater than about 37° C., a second water soluble surfactant having a cloud point greater than about 37° C., wherein a mixture of the first surfactant and the second surfactant comprises a cloud point less than about 37° C.Type: GrantFiled: December 12, 2011Date of Patent: December 17, 2013Assignee: PruGen IP Holdings, Inc.Inventor: Bhiku G. Patel
-
Patent number: 8604082Abstract: The present invention belongs to the fields of pharmacology, medicine and medicinal chemistry, and provides methods and compositions for treating sexual dysfunction; more particularly, the invention relates to treatment of premature ejaculation in humans.Type: GrantFiled: December 11, 2006Date of Patent: December 10, 2013Assignee: Trinity Laboratories, Inc.Inventor: Chandra U. Singh
-
Patent number: 8598191Abstract: The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid.Type: GrantFiled: May 21, 2012Date of Patent: December 3, 2013Assignee: Supernus Pharmaceuticals, Inc.Inventors: Likan Liang, Niraj Shah, Padmanabh P. Bhatt, Scott Ibrahim
-
Patent number: 8597681Abstract: Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.Type: GrantFiled: June 22, 2011Date of Patent: December 3, 2013Assignee: Mallinckrodt LLCInventors: Jae Han Park, Tiffani Eisenhauer, Anish Dhanarajan, Vishal K. Gupta, Stephen Overholt
-
Publication number: 20130317051Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.Type: ApplicationFiled: August 1, 2013Publication date: November 28, 2013Applicants: Purdue Pharma L.P., PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.Inventors: Benjamin Oshlack, Curtis Wright, Christopher Breder
-
Publication number: 20130317052Abstract: The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal mobility disorders.Type: ApplicationFiled: November 24, 2010Publication date: November 28, 2013Applicant: Dong-A ST Co., Ltd.Inventors: Miwon Son, Tae Ho Lee, Sang Zin Choi, Nam Joon Baek, Kang Ro Lee, Ki Hyun Kim, Soon Hoe Kim
-
Publication number: 20130309326Abstract: Methods and materials related to the use of morphine, morphine precursors (e.g., reticuline), and inhibitors of morphine synthesis or activity to treat diseases, to reduce inflammation, or to restore normal function are provided.Type: ApplicationFiled: June 21, 2013Publication date: November 21, 2013Applicant: The Research Foundation of State University of New YorkInventors: George B. Stefano, Patrick Cadet, Kirk J. Mantione, Wei Zhu
-
Publication number: 20130310415Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.Type: ApplicationFiled: July 24, 2013Publication date: November 21, 2013Applicant: Concert Pharmaceuticals Inc.Inventor: Roger Tung
-
Publication number: 20130281388Abstract: The invention relates a composition comprising an opioid agonist and Compound-1:Type: ApplicationFiled: December 17, 2012Publication date: October 24, 2013Inventor: Alkermes Pharma Ireland Limited
-
Publication number: 20130281483Abstract: The present invention provides a compound of formula I: wherein X?, R1, and R2 are as defined herein, and compositions thereof; useful as a peripheral mu opioid receptor antagonist.Type: ApplicationFiled: November 9, 2012Publication date: October 24, 2013Applicant: Wyeth LLCInventor: Wyeth LLC
-
Patent number: 8563572Abstract: Compounds of formulas: are disclosed. The compounds are useful for ameliorating the side effects of therapeutic opiates.Type: GrantFiled: August 9, 2012Date of Patent: October 22, 2013Assignee: Rensselaer Polytechnic InstituteInventor: Mark P. Wentland
-
Publication number: 20130274282Abstract: Pain and/or neurological disorders may be treated by administering a therapeutically effective amount of dextromethorphan and a therapeutically effective amount of a compound such as celecoxib that inhibits the metabolism of dextromethorphan, to a person in need thereof. The two compounds may be administered separately, or in a single dosage form or composition as described herein.Type: ApplicationFiled: April 4, 2013Publication date: October 17, 2013Inventor: Herriot Tabuteau
-
Publication number: 20130273153Abstract: Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.Type: ApplicationFiled: June 22, 2011Publication date: October 17, 2013Inventors: Jae Han Park, Tiffani Eisenhauer, Anish Dhanarajan, Vishal K. Gupta, Stephen Overholt
-
Publication number: 20130273152Abstract: This invention provides an oral pharmaceutical composition comprising a physiologically tolerable shell containing a drug of abuse within an oil comprising physiologically tolerable unsaturated fatty acids.Type: ApplicationFiled: April 11, 2011Publication date: October 17, 2013Applicant: AYANDA GROUP ASInventors: Kurt Ingar Draget, Ingvild Johanne Haug, Steinar Johan Engelsen, Tore Seternes
-
Publication number: 20130274280Abstract: This invention provides an oral pharmaceutical composition comprising a physiologically tolerable gelled oil-in-water emulsion containing a drug of abuse.Type: ApplicationFiled: April 11, 2011Publication date: October 17, 2013Applicant: AYANDA GROUP ASInventors: Kurt Ingar Draget, Ingvild Johanne Haug, Steinar Johan Engelsen, Tore Seternes, Magnus N. Hattrem
-
Patent number: 8557837Abstract: The invention relates to sinomenine derivatives, methods for their synthesis and their applications. The sinomenine derivatives include oxidation derivatives, and C-10 substituted sinomenine derivatives. Based on the readily oxidizable phenol group on sinomenine structure, using oxidation, oxidative dearomatization, or conjugated addition aromatization, one can introduce C-10 substitutions to synthesize the sinomenine derivatives. The sinomenine derivatives of the invention have the following structures: Using in vitro TNF-? inhibition assay, the activities of the synthetic compounds are assessed. Results from these assays shown that most compounds have anti-inflammatory effects, and some compounds have better activities than that of sinomenine. These compounds may be used in treating immune diseases such as rheumatoid arthritis (RA).Type: GrantFiled: February 9, 2011Date of Patent: October 15, 2013Assignees: Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of SciencesInventors: Zhujun Yao, Bing Sun, Yangtong Lou, Zhenyu Yang, Aizhong Chen, Zhao Ma
-
Patent number: 8557784Abstract: The present invention provides a pharmaceutically acceptable compound, a pharmaceutical composition comprising the above-mentioned pharmaceutically acceptable compound. The pharmaceutically acceptable compound provided by the present invention is a salt of a basic group-containing morphinan derivative and a carboxyl group-containing glycyrrhizinic acid and has the ability to be used to manufacture medicaments for treating and/or preventing cough, ameliorating pains, treating respiratory system diseases, treating cardiovascular diseases and treating liver diseases.Type: GrantFiled: July 7, 2011Date of Patent: October 15, 2013Assignee: Standard Chem. & Pharm. Co., Ltd.Inventors: Chin-Tsai Fan, Cheng-Shun Lai, Wen-Yen Yeh, Yu-Ying Liu
-
Patent number: 8546348Abstract: Disclosed are methods for treating pain in a subject. The method includes upregulating expression of opioid receptors in the subject's dorsal root ganglion or trigeminal neurons. Also disclosed are methods of treating neuropathic and/or chronic pain in a subject. The method includes upregulating expression of ?-opioid or ?-opioid receptors in the subject's dorsal root ganglion or trigeminal neurons.Type: GrantFiled: October 4, 2010Date of Patent: October 1, 2013Assignee: The Board of Regents of the University of Texas SystemInventors: Li-Yen Mae Huang, Yanping Gu
-
Patent number: 8541436Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.Type: GrantFiled: May 31, 2011Date of Patent: September 24, 2013Assignee: Concert Pharmaceuticals Inc.Inventor: Roger Tung
-
Publication number: 20130245057Abstract: The present invention relates to methods, compositions, and kits for treating or preventing symptoms of hormonal variation. The method comprises the steps of administering an effective amount of Dextromethorphan or Dextrorphan, or a pharmaceutically acceptable salt thereof, to a subject having one or more symptoms of hormonal variations.Type: ApplicationFiled: May 3, 2013Publication date: September 19, 2013Applicant: FERVENT PHARMACEUTICALS, LLCInventor: George R. Royster, JR.
-
Publication number: 20130237559Abstract: The present invention provides sustained-release oral pharmaceutical compositions and methods of use. The sustained-release oral pharmaceutical compositions include an amine-containing compound (e.g., an opioid) (including salts thereof) and a pharmaceutically acceptable salt of a non-NSAID cyclic organic acid compound.Type: ApplicationFiled: June 29, 2011Publication date: September 12, 2013Inventors: Ronnie Ortiz, James S. Jensen, Kristopher R. Lundell, Victoria Ann O'Neill, Sean Mahoney
-
Publication number: 20130231361Abstract: 4-Hydroxybenzomorphans containing carboxamide or thiocarboxamide at the 3-position are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications. A compound of formula is disclosed, as are pharmaceutically acceptable acid addition salts, such as acetic, benzenesulfonic (besylate), benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid or p-toluenesulfonic acid salts. These compounds are useful for the treatment of pain.Type: ApplicationFiled: April 15, 2013Publication date: September 5, 2013Applicant: Rensselaer Polytechnic InstitueInventor: Mark P. WENTLAND